WCLC 2025: Combination therapy achieves durable response in advanced lung cancer patients
KRAS G12C mutations are among the most common drivers of?non-small cell lung cancer (NSCLC), yet first-line targeted therapy options remain limited. Olomorasib, a selective KRAS G12C inhibitor, has shown promising results in combination with chemoimmunotherapy. In an integrated analysis from the Phase I LOXO-RAS-20001 and Phase III SUNRAY-01 trials, Marcelo V. Negrao, M.D., and colleagues examined the safety and preliminary efficacy...
WCLC 2025: Bispecific antibody dose shows promising potential for extensive-stage SCLC
Pumitamig is a novel bispecific antibody targeting both the PD-L1 checkpoint and VEGF, a driver of angiogenesis, being studied in patients...
WCLC 2025: Brigatinib with local therapy can potentially improve outcomes for advanced NSCLC
Almost all patients with ALK-rearranged non-small cell lung cancer (NSCLC) end up with an incomplete response to targeted therapy with tyrosine...
WCLC 2025: Innovative ADC therapy shows promise in hard-to-treat small cell lung cancer
Small cell lung cancer (SCLC)?remains one of the most aggressive and difficult-to-treat forms of lung cancer, with few effective therapies for patients who relapse. The SEZ6 protein is highly expressed in SCLC and is a promising therapeutic target. In a Phase I study, researchers led by?Lauren Byers M.D., evaluated the safety and efficacy of ABBV-706 ¨C an antibody-drug conjugate (ADC) that targets SEZ6 and delivers a chemotherapy...
Novel sequencing technology links DNA and RNA to provide molecular insights into breast cancer progression
Breast cancer often starts in the epithelial cells lining the milk ducts and lobules, but there are many subtypes that make it challenging...
Targeted radiation helps patients with kidney cancer?delay systemic therapy?
Some patients with?clear cell renal cell carcinoma (ccRCC) ¨C the most common type of?kidney cancer?in adults ¨C experience oligometastatic...
Researchers identify predictive biomarkers for oral cancer metastasis
Most oral cancers start in squamous cells lining the mouth and tongue, and frequently metastasize to the lymph nodes. To identify potential...
First-in-class pan-KRAS inhibitor shows strong antitumor activity in preclinical models
KRAS is the most commonly mutated gene in cancer, but targeting the mutant protein is notoriously difficult because current therapies work...